Copyright
©The Author(s) 2024.
World J Diabetes. Apr 15, 2024; 15(4): 724-734
Published online Apr 15, 2024. doi: 10.4239/wjd.v15.i4.724
Published online Apr 15, 2024. doi: 10.4239/wjd.v15.i4.724
Figure 1 Teneligliptin ameliorated myocardial hypertrophy in streptozotocin-induced diabetic mice.
A: Molecular structure of teneligliptin; B: Quantitative analysis of cardiomyocyte area; C: Heart weight/tibia length. aP < 0.05 vs control group; bP < 0.05 vs streptozotocin group, n = 8. STZ: Streptozotocin.
- Citation: Zhang GL, Liu Y, Liu YF, Huang XT, Tao Y, Chen ZH, Lai HL. Teneligliptin mitigates diabetic cardiomyopathy by inhibiting activation of the NLRP3 inflammasome. World J Diabetes 2024; 15(4): 724-734
- URL: https://www.wjgnet.com/1948-9358/full/v15/i4/724.htm
- DOI: https://dx.doi.org/10.4239/wjd.v15.i4.724